Page last updated: 2024-08-24

irinotecan and phenobarbital

irinotecan has been researched along with phenobarbital in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (7.14)	18.2507
2000's	8 (57.14)	29.6817
2010's	5 (35.71)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Gupta, E; Ramirez, J; Ratain, MJ; Wang, X	1
Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V	1
Cheng, C; Das, S; Di Rienzo, A; Grimsley, C; Innocenti, F; Kuttab-Boulos, H; Ramírez, J; Ratain, MJ	1
Innocenti, F; Mani, S; Prado, M; Ramírez, J; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ	1
Ando, M; Ando, Y; Hasegawa, Y; Imaizumi, K; Kitagawa, C; Sekido, Y; Shimokata, K; Wakai, K	1
Das, S; Fackenthal, DL; Graber, AY; Innocenti, F; Komoroski, BJ; Mirkov, S; Ramírez, J; Ratain, MJ; Schuetz, EG; Strom, SC	1
Cai, H; Chen, S; Hotz, K; La Placa, DB; Nguyen, N; Peterkin, V; Stevens, JC; Tukey, RH; Yang, YS	1
Ames, MM; Berg, AK; Buckner, JC; Galanis, E; Jaeckle, KA; Reid, JM	1

Reviews

1 review(s) available for irinotecan and phenobarbital

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for irinotecan and phenobarbital

Article	Year
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clinical pharmacology and therapeutics, 2004, Volume: 76, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endpoint Determination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Half-Life; Humans; Hypnotics and Sedatives; Immunosuppressive Agents; Irinotecan; Lymphoma; Male; Middle Aged; Neoplasms; Phenobarbital	2004
Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure. Journal of clinical pharmacology, 2015, Volume: 55, Issue:11 Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carbamazepine; Drug Interactions; Enzyme Induction; Female; Glioma; Glucuronates; Humans; Irinotecan; Male; Middle Aged; Phenobarbital; Phenytoin	2015

Article

Year

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.

Clinical pharmacology and therapeutics, 2004, Volume: 76, Issue:5

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endpoint Determination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Half-Life; Humans; Hypnotics and Sedatives; Immunosuppressive Agents; Irinotecan; Lymphoma; Male; Middle Aged; Neoplasms; Phenobarbital

2004

Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.

Journal of clinical pharmacology, 2015, Volume: 55, Issue:11

Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Carbamazepine; Drug Interactions; Enzyme Induction; Female; Glioma; Glucuronates; Humans; Irinotecan; Male; Middle Aged; Phenobarbital; Phenytoin

2015

Other Studies

11 other study(ies) available for irinotecan and phenobarbital

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer chemotherapy and pharmacology, 1997, Volume: 39, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Female; Glucuronates; Glucuronosyltransferase; Irinotecan; Metabolic Clearance Rate; Phenobarbital; Rats; Rats, Wistar; Valproic Acid	1997
Influence of phenytoin on the disposition of irinotecan: a case report. Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:2 Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Disease Progression; Drug Interactions; Enzyme Induction; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Melphalan; Mixed Function Oxygenases; Neoplasm Recurrence, Local; Ondansetron; Phenobarbital; Phenytoin; Pineal Gland; Pinealoma; Prodrugs; Salvage Therapy; Seizures	2002
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics, 2002, Volume: 12, Issue:9 Topics: Base Sequence; Bilirubin; Black or African American; Camptothecin; Genotype; Glucuronides; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Microsomes, Liver; Molecular Sequence Data; Phenobarbital; Polymorphism, Genetic; Promoter Regions, Genetic; Topoisomerase I Inhibitors; White People	2002
Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenetics and genomics, 2005, Volume: 15, Issue:1 Topics: Adult; Aged; Alleles; Camptothecin; Enhancer Elements, Genetic; Excitatory Amino Acid Antagonists; Female; Genetic Variation; Genotype; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Linkage Disequilibrium; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pharmacogenetics; Phenobarbital; Polymorphism, Genetic; Promoter Regions, Genetic; Risk; Time Factors	2005
Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenetics and genomics, 2006, Volume: 16, Issue:2 Topics: Adolescent; Adult; Aged; Camptothecin; Child; Child, Preschool; Female; Glucuronosyltransferase; Hepatocytes; Humans; Infant; Irinotecan; Liver; Male; Middle Aged; Pharmacogenetics; Phenobarbital; Polymorphism, Single Nucleotide	2006
A humanized UGT1 mouse model expressing the UGT1A128 allele for assessing drug clearance by UGT1A1-dependent glucuronidation. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:5* Topics: Alleles; Animals; Anticholesteremic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Azetidines; Biocatalysis; Camptothecin; Dimethyl Sulfoxide; Enzyme Induction; Ezetimibe; Gene Expression; Glucuronic Acid; Glucuronosyltransferase; Humans; Irinotecan; Kinetics; Liver; Male; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microsomes, Liver; Models, Animal; Naloxone; Pharmaceutical Preparations; Phenobarbital; UDP-Glucuronosyltransferase 1A9	2010